Moderna

Organization

On 2 shows in Health & Science this week · 1.6× usual · most on BioCentury This Week

Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts. It develops RNA therapeutics, especially mRNA vaccines, using messenger RNA to instruct cells to produce proteins that can generate immune responses; its pipeline also includes programs targeting infectious diseases and cancer.

Rank this week

#121new
#359 over 30 days

Share of the conversation

0.7‰
1.6× usual level

1.1‰ of what listeners heard

Reach this week

2 shows
2 episodes · ~250k plays

Tone this week

—

Not enough signal yet (fewer than 3 episodes scored).

Share of the conversation

Mentions of Moderna per 1,000 mentions of anything, 7-day rolling, health & science.

0.0‰1‰2‰3‰usual level · 0.45‰Aug 25Sep 16Oct 9Oct 31Nov 22
Show the data
DayShare (7-day)Mentions
Sep 30.23‰1
Oct 40.23‰1
Oct 80.45‰1
Oct 100.65‰1
Oct 120.68‰1
Oct 130.91‰1
Oct 161.38‰3
Oct 171.41‰1
Oct 231.29‰5
Oct 271.81‰3
Oct 301.72‰4
Nov 160.35‰2
Nov 170.67‰2

Why is it trending?· Last 7 days

Moderna’s melanoma vaccine data prompts debate over cancer-vaccine prospects

Moderna and Merck released anticipated results for a personalized mRNA vaccine in resected melanoma, with the study described as positive and its primary endpoint achieved.[1][2][3]

On BioCentury This Week, Lauren Martz said melanoma is both a useful test of immunotherapy and a difficult setting because other immunotherapies have worked there.[4]

On Breaking Biotech, Matthew Cloutier discussed the full Intrapath 001 results and said Moderna’s sell-off would probably continue.[5]

The Readout Loud questioned whether the results were the conference’s most impactful, while Biotech Hangout contrasted Moderna’s platform with a different vaccine approach and raised questions about lipid nanoparticles.[3][6]

Sources · 6 moments

  1. 1.
    BioCentury This Week · Ep. 394 - Security concerns in U.S., China reshaping biotech
    Jeff Cranmer · Oct 27 · Listen at 0:52 ↗
    “with a $1 .3 billion deal with Gilead. What is the tech that attracted the Bay Area big biotech? And last week, much anticipated data from Merck and Moderna on their melanoma vaccine bring the adoption test into focus. Joining me to discuss”
  2. 2.
    Breaking Biotech · 120 - Breaking Biotech Week End Wrap Up - Oct 25th, 2026
    Matthew Cloutier · Oct 26 · Listen at 6:05 ↗
    “matter because there might just be enough people willing to pump this thing up as much as it is like a huge, pretty, pretty large market cap right now. There's a lot going on there. What ended up happening is at ESMO, Moderna was scheduled”
  3. 3.
    The Readout Loud · 419: Assessing Merck and Moderna's mRNA cancer vaccine
    Allison DeAngelis · Oct 30 · Listen at 1:53 ↗
    “Well, okay. Before you go back to your Mai Tais or whatever you're enjoying, tell us about ESMO. I want to start off with the juiciest, most eye-catching news of the week, which were these results from Moderna and Merck's cancer vaccine. Wh”
  4. 4.
    BioCentury This Week · Ep. 394 - Security concerns in U.S., China reshaping biotech
    Lauren Martz · Oct 27 · Listen at 27:48 ↗
    “Well, so first I would say we don't know how large that effect size has to be. That's still an unknown at this point. But I think this could go either way. So Moderna and Merck went into melanoma as their first indication, which can be a go”

Written by AI from the cited moments; every quote is checked against the transcript.

Who is saying what about Moderna

Verified quotes from the last 90 days: who made the most claims, and which way they leaned.

27 more with Pro.

Discussed alongside

Names that come up in the same conversations as Moderna.

See 5 more with Pro

Embed this

Paste this on your site to show Moderna's current trend:

<iframe src="https://podlume.ai/embed/e/moderna" width="360" height="220" style="border:0" loading="lazy" title="Moderna on PodLume Trends"></iframe>